Multiple myeloma
Approval decisionStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Anito-cel (anitocabtagene autoleucel)(CART-ddBCMA) | Multiple myeloma | PDUFA | Dec 23, 2026 | — |
Upcoming milestones
Multiple myeloma
Approval decisionCompany profile
Arcellx Inc is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.